^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cholangiocarcinoma

    Related cancers:
    1d
    Gross Intrahepatic Mass Formation Predicts the Primary Site of Perihilar Cholangiocarcinoma Based on Molecular Pathologic Studies. (PubMed, J Hepatobiliary Pancreat Sci)
    Gross intrahepatic mass formation indicates an intrahepatic contextual profile and provides a useful criterion for subclassifying hCCA. This contextual framework shows that hCCA-M and hCCA-NM represent biologically distinct tumor groups.
    Journal
    |
    CLDN18 (Claudin 18) • MSLN (Mesothelin) • SERPINA1 (Serpin Family A Member 1)
    3d
    Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition. (PubMed, Arch Med Res)
    CCA cells with upregulated CDK2 and its cyclin partners in HG were more sensitive to tagtociclib at a higher dose. Cyclin E and cyclin A also regulated CCA metastasis by controlling epithelial-mesenchymal transition. Targeting CDK2 and its associated cyclins in CCA cells demonstrated therapeutic potential that requires further translational and clinical verification.
    Journal
    |
    CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
    |
    tegtociclib (PF-07104091)
    3d
    Retrospective analysis of perioperative coagulation function in patients with hepatocellular carcinoma complicated by cirrhosis (ChiCTR2500108758)
    P=N/A, N=600, Recruiting, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University | N=200 --> 600
    Enrollment change
    3d
    A single-arm, single-center, prospective clinical study of trastuzumab emtansine combined with GEMOX regimen as first-line treatment for advanced biliary system tumors (ChiCTR2600117154)
    P=N/A, N=20, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Kadcyla (ado-trastuzumab emtansine) • Loqtorzi (toripalimab-tpzi)
    3d
    Efficacy and safety of Gemox-HAIC in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in the treatment of advanced biliary-derived malignancies: a case series (ChiCTR2600116095)
    P=N/A, N=40, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New trial
    3d
    Clinical Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Systemic Therapy in Patients with Unresectable Intrahepatic Cholangiocarcinoma Refractory to First-Line Treatment (ChiCTR2500115791)
    P=N/A, N=40, Not yet recruiting, The second affiliated hospital of nanchang university; The second affiliated hospital of nanchang university
    New trial
    3d
    Exploratory Clinical Study of the Novel QYK-101 In Situ Vaccine Strategy as an Adjuvant Therapy for Recurrent or Metastatic Solid Tumors (ChiCTR2500114428)
    P=N/A, N=3, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    3d
    A study on the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with gemcitabine and albumin-bound paclitaxel (GA) as first-Line therapy for advanced cholangiocarcinoma (ChiCTR2500114460)
    P=N/A, N=25, Not yet recruiting, Yunnan Cancer Hospital; Yunnan Cancer Hospital
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    3d
    The Construction and application of an intelligent prediction model related to the biological behavior and prognosis of intrahepatic cholangiocarcinoma based on multimodal information flow (ChiCTR2500113110)
    P=N/A, N=0, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    3d
    Research on the Detection and Intelligent Classification of Focal Liver Lesions in High-Risk HCC Populations Using a Visual Transformer Based on Attention Mechanism (ChiCTR2500112712)
    P=N/A, N=1500, Recruiting, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
    New trial
    3d
    Unmasking the Bacterial Culprits in Cancer-Related Bile Duct Infections (ChiCTR2500112252)
    P=N/A, N=100, Not yet recruiting, Lishui Central Hospital; Lishui Central Hospital
    New trial
    3d
    Efficacy of Avatrombopag in Primary/Secondary Prevention of ADC Drug-Induced Thrombocytopenia in Breast Cancer (ChiCTR2500112156)
    P=N/A, N=72, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New trial
    |
    Herceptin (trastuzumab)